Format

Send to

Choose Destination
Emerg Infect Dis. 2013 Mar;19(3):416-24. doi: 10.3201/eid1903.120998.

Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.

Author information

1
Albert Einstein College of Medicine, Bronx, NY 10461, USA. max.odonnell@einstein.yu.edu

Abstract

High mortality rates have been reported for patients co-infected with extensively drug-resistant tuberculosis (XDR-TB) and HIV, but treatment outcomes have not been reported. We report treatment outcomes for adult XDR TB patients in KwaZulu-Natal Province, South Africa. Initial data were obtained retrospectively, and outcomes were obtained prospectively during 24 months of treatment. A total of 114 XDR TB patients were treated (median 6 drugs, range 3-9 drugs); 82 (73%) were HIV positive and 50 (61%) were receiving antiretroviral therapy. After receiving treatment for 24 months, 48 (42%) of 114 patients died, 25 (22%) were cured or successfully completed treatment, 19 (17%) withdrew from the study, and 22 (19%) showed treatment failure. A higher number of deaths occurred among HIV-positive patients not receiving antiretroviral therapy and among patients who did not show sputum culture conversion. Culture conversion was a major predictor of survival but was poorly predictive (51%) of successful treatment outcome.

KEYWORDS:

HIV; South Africa; XDR TB; bacteria; co-infection; extensively drug-resistant tuberculosis; treatment outcomes; tuberculosis and other mycobacteria; viruses

PMID:
23622055
PMCID:
PMC3647656
DOI:
10.3201/eid1903.120998
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for CDC-NCEZID Icon for PubMed Central
Loading ...
Support Center